Volume : 12, Issue : 11, November – 2025
Title:
A STUDY ON ASSOCIATION OF LIPOPROTEIN(A) LEVELS WITH CARDIOVASCULAR RISK
Authors :
Mr. Manish B Kori , Dr.Anilkumar S Kusnoor
Abstract :
Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease, but its prevalence and association with other risk factors in patients with heart disease is not well-studied. This study was conducted to assess the levels of Lp(a) in cardiovascular patients and evaluate its relationship with lipid profile, body mass index (BMI), and cardiovascular risk.
Methods: A total of 100 patients with confirmed cardiovascular disease were enrolled using convenience sampling. Demographic data, BMI, and cardiovascular risk factors were recorded. Fasting blood samples were analyzed for lipid profile and Lp(a) levels. The Framingham 10-year cardiovascular risk score was calculated, and the association between Lp(a) and other parameters was assessed using correlation analysis.
Results: Elevated Lp(a) levels (>30 mg/dL) were observed in 56% of patients. Lp(a) positively correlated with LDL-C, total cholesterol, triglycerides, BMI, and Framingham risk scores, and inversely with HDL-C. Patients with higher risk scores had higher mean Lp(a) levels.
Conclusion: Lp(a) is a significant and independent marker of cardiovascular risk. Routine assessment may improve early identification and management of high-risk patients.
Cite This Article:
Please cite this article in press Manish B Kori et al., A Study On Association Of Lipoprotein(A) Levels With Cardiovascular Risk, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, McGhie DV, Mwangi J, Pervan B, Narula J, Pineiro D, Pinto FJ. The Heart of the World. Glob Heart. 2024 Jan 25;19(1):11.
2. Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson CO, LeGrand KE, et al. Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990–2021. J Am Coll Cardiol. 2022; 80: 2372–2425.
3. Liang Q, Zhang G, Jiang L. Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study. BMC Nephrol. 2024 Aug 1;25(1):250.
4. Gelfert GG, Grittner U, Kuhnert R, Scheidt-Nave C, Endres M, Nave AH. Association of Lipoprotein(a) With Cardiovascular and Cerebrovascular Disease in a Nationally Representative Cohort of Germany. JACC Adv. 2025 Aug;4(8):102015.
5. Alebna PL, Ambrosio M, Martin M, Martey S, Spitz JA, Sharma G, Van Tassell B, Dixon DL, Hundley WG, Salloum FN, Mehta A. Association of Lipoprotein(a) with cardiovascular events among individuals with autoimmune conditions. Atherosclerosis. 2025 Jul;406:119244.
6. Reyes-Soffer G. The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk. Curr Opin Lipidol. 2021 Jun 1;32(3):163-166
7. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60
8. Parcha V, Bittner VA. Lipoprotein (a) in primary cardiovascular disease prevention is actionable today. Am Heart J Plus. 2025 Jul 21;57:100581.
9. Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A, Biolo G. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721.
10. Arsenault B.J., Kamstrup P.R. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective. Atherosclerosis. 2022;349:7–16
11. Bhatia HS, Wandel S, Willeit P, Lesogor A, Bailey K, Ridker PM, Nestel P, Simes J, Tonkin A, Schwartz GG, Colhoun H, Wanner C, Tsimikas S. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2025 Jan 28;151(4):312-321.
12. Doherty S, Hernandez S, Rikhi R, Mirzai S, De Los Reyes C, McIntosh S, Block RC, Shapiro MD. Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease. Curr Cardiovasc Risk Rep. 2025;19(1):8.
13. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O’Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020 Jan 16;382(3):244-255.
14. Wong ND, Fan W, Hu X, Ballantyne C, Hoodgeveen RC, Tsai MY, Browne A, Budoff MJ. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort. J Am Coll Cardiol. 2024 Apr 23;83(16):1511-1525.
15. Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024 Apr 3;18:100651